Literature DB >> 10450747

Growth factor independence and BCR/ABL transformation: promise and pitfalls of murine model systems and assays.

S Ghaffari1, G Q Daley, H F Lodish.   

Abstract

The expression of the BCR-ABL fusion oncoprotein in primitive hematopoietic cells results in chronic myeloid leukemia. Over the past decade studies of several in vitro and in vivo cell systems revealed multiple signal transduction pathways activated by BCR-ABL. However, the precise function of BCR-ABL in the pathogenesis of CML is still unclear. The goal of this review is to synthesize data on intracellular signaling in the context of the diverse murine assay systems employed. We emphasize the importance of in vivo assays and assays using primary cells in understanding the biology of CML and the molecular mechanisms by which BCR-ABL exerts its effects.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10450747     DOI: 10.1038/sj.leu.2401467

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  9 in total

1.  Retrovirus-mediated gene transfer of MLL-ELL transforms primary myeloid progenitors and causes acute myeloid leukemias in mice.

Authors:  C Lavau; R T Luo; C Du; M J Thirman
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

2.  hnRNP A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and BCR/ABL leukemogenesis.

Authors:  Angela Iervolino; Giorgia Santilli; Rossana Trotta; Clara Guerzoni; Vincenzo Cesi; Anna Bergamaschi; Carlo Gambacorti-Passerini; Bruno Calabretta; Danilo Perrotti
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

3.  A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation.

Authors:  S Prabhu; D Saadat; M Zhang; L Halbur; J P Fruehauf; S T Ong
Journal:  Oncogene       Date:  2006-08-28       Impact factor: 9.867

Review 4.  Molecular and cellular bases of chronic myeloid leukemia.

Authors:  Yaoyu Chen; Cong Peng; Dongguang Li; Shaoguang Li
Journal:  Protein Cell       Date:  2010-02-06       Impact factor: 14.870

5.  ROS-mediated amplification of AKT/mTOR signalling pathway leads to myeloproliferative syndrome in Foxo3(-/-) mice.

Authors:  Safak Yalcin; Dragan Marinkovic; Sathish Kumar Mungamuri; Xin Zhang; Wei Tong; Rani Sellers; Saghi Ghaffari
Journal:  EMBO J       Date:  2010-11-26       Impact factor: 11.598

Review 6.  FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis.

Authors:  Zainab Jagani; Amrik Singh; Roya Khosravi-Far
Journal:  Biochim Biophys Acta       Date:  2007-10-16

7.  Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor.

Authors:  Saghi Ghaffari; Zainab Jagani; Claire Kitidis; Harvey F Lodish; Roya Khosravi-Far
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-15       Impact factor: 11.205

8.  Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens.

Authors:  Alice C Fan; Debabrita Deb-Basu; Mathias W Orban; Jason R Gotlib; Yasodha Natkunam; Roger O'Neill; Rose-Ann Padua; Liwen Xu; Daryl Taketa; Amy E Shirer; Shelly Beer; Ada X Yee; David W Voehringer; Dean W Felsher
Journal:  Nat Med       Date:  2009-04-12       Impact factor: 53.440

Review 9.  Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia.

Authors:  Yaoyu Chen; Shaoguang Li
Journal:  Onco Targets Ther       Date:  2014-01-31       Impact factor: 4.147

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.